{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T07:37:07Z","timestamp":1753601827117},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T00:00:00Z","timestamp":1495411200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s00280-017-3316-7","type":"journal-article","created":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T11:13:39Z","timestamp":1495451619000},"page":"37-44","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The renal safety and efficacy of combined gemcitabine plus cisplatin and gemcitabine plus carboplatin chemotherapy in Chinese patients with a solitary kidney after nephroureterectomy"],"prefix":"10.1007","volume":"80","author":[{"given":"Peng","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Ren","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cui","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ried","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-Fei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Qi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Xia","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,22]]},"reference":[{"key":"3316_CR1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.critrevonc.2016.03.014","volume":"102","author":"GY Ho","year":"2016","unstructured":"Ho GY, Woodward N, Coward JI (2016) Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies. Crit Rev Oncol Hematol 102:37\u201346","journal-title":"Crit Rev Oncol Hematol"},{"key":"3316_CR2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clgc.2016.05.003","volume":"15","author":"A Necchi","year":"2017","unstructured":"Necchi A, Pond GR, Raggi D et al (2017) Efficacy and safety of gemcitabine plus either taxane or carboplatin in the first-line setting of metastatic urothelial carcinoma: a systematic review and meta-analysis. Clin Genitourin Cancer 15:23\u201330.e2","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"3316_CR3","first-page":"1","volume":"59","author":"T Sumiyoshi","year":"2013","unstructured":"Sumiyoshi T, Matsumoto K, Utsunomiya N, Segawa T, Muguruma K, Kawakita M (2013) Gemcitabine and cisplatin (GC) or gemcitabine and carboplatin (GCarbo) in patients with metastatic urothelial cancer. Hinyokika Kiyo 59(1):1\u20136","journal-title":"Hinyokika Kiyo"},{"issue":"24","key":"3316_CR4","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1002\/cncr.26172","volume":"117","author":"M Vassilakopoulou","year":"2011","unstructured":"Vassilakopoulou M, de la Motte Rouge T, Colin P et al (2011) Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study. Cancer 117(24):5500\u20135508","journal-title":"Cancer"},{"key":"3316_CR5","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1111\/j.1464-410X.2012.11341.x","volume":"110","author":"BP Rai","year":"2012","unstructured":"Rai BP, Shelley M, Coles B, Somani B, Nabi G (2012) Surgical management for upper urinary tract transitional cell carcinoma (UUT-TCC): a systematic review. BJU Int 110:1426\u20131435","journal-title":"BJU Int"},{"key":"3316_CR6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7\u201330","journal-title":"CA Cancer J Clin"},{"key":"3316_CR7","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1464-410X.2007.06801.x","volume":"99","author":"DJ Painter","year":"2007","unstructured":"Painter DJ, Timoney AG, Denton K, Alken P, Keeley FX (2007) The modern management of upper urinary tract urothelial cancer: tumour diagnosis, grading and staging. BJU Int 99:973\u2013977","journal-title":"BJU Int"},{"issue":"11","key":"3316_CR8","doi-asserted-by":"crossref","first-page":"495.e9","DOI":"10.1016\/j.urolonc.2015.07.001","volume":"33","author":"MC Hsieh","year":"2015","unstructured":"Hsieh MC, Chiang PH, Rau KM, Chen YY, Su YL, Huang CH (2015) The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy. Urol Oncol 33(11):495.e9\u2013495.e14","journal-title":"Urol Oncol"},{"issue":"2","key":"3316_CR9","first-page":"163","volume":"46","author":"E Kikuchi","year":"2016","unstructured":"Kikuchi E, Miyazaki J, Yuge K et al (2016) Do metastatic upper tract urothelial carcinoma and bladder carcinoma have similar clinical responses to systemic chemotherapy? A Japanese multi-institutional experience. Jpn J Clin Oncol 46(2):163\u2013169","journal-title":"Jpn J Clin Oncol"},{"issue":"8","key":"3316_CR10","doi-asserted-by":"crossref","first-page":"686","DOI":"10.7150\/jca.7326","volume":"4","author":"TS Kim","year":"2013","unstructured":"Kim TS, Oh JH, Rhew HY (2013) The efficacy of adjuvant chemotherapy for locally advanced upper tract urothelial cell carcinoma. J Cancer 4(8):686\u2013690","journal-title":"J Cancer"},{"issue":"4","key":"3316_CR11","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.urolonc.2010.07.016","volume":"31","author":"F Audenet","year":"2013","unstructured":"Audenet F, Yates DR, Cussenot O, Roupr\u00eat M (2013) The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC). Urol Oncol 31(4):407\u2013413","journal-title":"Urol Oncol"},{"issue":"11","key":"3316_CR12","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/iju.12868","volume":"22","author":"K Fujita","year":"2015","unstructured":"Fujita K, Inamoto T, Yamamoto Y et al (2015) Role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma and the prognostic significance of C-reactive protein: a multi-institutional, retrospective study. Int J Urol 22(11):1006\u20131012","journal-title":"Int J Urol"},{"issue":"2","key":"3316_CR13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.juro.2015.03.077","volume":"194","author":"YC Huang","year":"2015","unstructured":"Huang YC, Chen MF, Shi CS et al (2015) The efficacy of postoperative adjuvant chemotherapy for patients with pT3N0M0 upper tract urothelial carcinoma. J Urol 194(2):323\u2013329","journal-title":"J Urol"},{"key":"3316_CR14","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.eururo.2015.06.044","volume":"68","author":"M Roupr\u00eat","year":"2015","unstructured":"Roupr\u00eat M, Babjuk M, Comp\u00e9rat E et al (2015) European Association of Urology Guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. Eur Urol 68:868\u2013879","journal-title":"Eur Urol"},{"key":"3316_CR15","first-page":"419028","volume":"2009","author":"PH O\u2019Donnell","year":"2009","unstructured":"O\u2019Donnell PH, Stadler WM (2009) The role of chemotherapy in upper tract urothelial carcinoma. Adv Urol 2009:419028","journal-title":"Adv Urol"},{"issue":"8","key":"3316_CR16","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jfma.2013.04.001","volume":"113","author":"G Xiong","year":"2014","unstructured":"Xiong G, Chen X, Li X et al (2014) Prevalence and factors associated with baseline chronic kidney disease in China: a 10-year study of 785 upper urinary tract urothelial carcinoma patients. J Formos Med Assoc 113(8):521\u2013526","journal-title":"J Formos Med Assoc"},{"issue":"12","key":"3316_CR17","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1002\/cncr.25043","volume":"116","author":"BR Lane","year":"2010","unstructured":"Lane BR, Smith AK, Larson BT et al (2010) Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer 116(12):2967\u20132973","journal-title":"Cancer"},{"issue":"4","key":"3316_CR18","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00280-010-1349-2","volume":"67","author":"KS Cho","year":"2011","unstructured":"Cho KS, Joung JY, Seo HK et al (2011) Renal safety and efficacy of cisplatin-based chemotherapy in patients with a solitary kidney after nephroureterectomy for urothelial carcinoma of the upper urinary tract. Cancer Chemother Pharmacol 67(4):769\u2013774","journal-title":"Cancer Chemother Pharmacol"},{"key":"3316_CR19","doi-asserted-by":"crossref","first-page":"10108","DOI":"10.1002\/chem.200700887","volume":"13","author":"M Pavelka","year":"2007","unstructured":"Pavelka M, Lucas MF, Russo N (2007) On the hydrolysis mechanism of the second-generation anticancer drug carboplatin. Chemistry 13:10108\u201310116","journal-title":"Chemistry"},{"issue":"1","key":"3316_CR20","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.eururo.2006.12.029","volume":"52","author":"L Dogliotti","year":"2007","unstructured":"Dogliotti L, Carten\u00ec G, Siena S et al (2007) Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 52(1):134\u2013141","journal-title":"Eur Urol"},{"issue":"33","key":"3316_CR21","doi-asserted-by":"crossref","first-page":"5634","DOI":"10.1200\/JCO.2008.21.4924","volume":"27","author":"M Santis De","year":"2009","unstructured":"De Santis M, Bellmunt J, Mead G et al (2009) Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer \u201cunfit\u201d for cisplatin-based chemotherapy: phase II\u2014results of EORTC study 30986. J Clin Oncol 27(33):5634\u20135639","journal-title":"J Clin Oncol"},{"issue":"2","key":"3316_CR22","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s12032-011-9824-0","volume":"29","author":"OO Faluyi","year":"2012","unstructured":"Faluyi OO, Masinghe SP, Hayward RL, Clive S (2012) Accuracy of GFR estimation by the Cockroft and Gault, MDRD, and Wright equations in oncology patients with renal impairment. Med Oncol 29(2):755\u2013760","journal-title":"Med Oncol"},{"issue":"9","key":"3316_CR23","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604\u2013612","journal-title":"Ann Intern Med"},{"issue":"4","key":"3316_CR24","first-page":"2015","volume":"34","author":"K Yoshida","year":"2014","unstructured":"Yoshida K, Yamazaki H, Nakamara S et al (2014) Comparison of common terminology criteria for adverse events v3.0 and radiation therapy oncology group toxicity score system after high-dose-rate interstitial brachytherapy as monotherapy for prostate cancer. Anticancer Res 34(4):2015\u20132018","journal-title":"Anticancer Res"},{"issue":"1","key":"3316_CR25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/MNM.0000000000000401","volume":"37","author":"M Aras","year":"2016","unstructured":"Aras M, Erdil TY, Dane F et al (2016) Comparison of WHO, RECIST 1.1, EORTC, and PERCIST criteria in the evaluation of treatment response in malignant solid tumors. Nucl Med Commun 37(1):9\u201315","journal-title":"Nucl Med Commun"},{"issue":"9","key":"3316_CR26","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1200\/JCO.1999.17.9.2876","volume":"17","author":"MJ Moore","year":"1999","unstructured":"Moore MJ, Winquist EW, Murray N et al (1999) Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17(9):2876\u20132881","journal-title":"J Clin Oncol"},{"issue":"21","key":"3316_CR27","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","volume":"23","author":"HV Maase der","year":"2005","unstructured":"der Maase HV, Sengelov L, Roberts JT et al (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23(21):4602\u20134608","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"3316_CR28","doi-asserted-by":"crossref","first-page":"v118","DOI":"10.1093\/annonc\/mdj965","volume":"17","author":"JT Roberts","year":"2006","unstructured":"Roberts JT, der Maase HV, Sengel\u00f8v L et al (2006) Long-term survival results of a randomized trial comparing gemcitabine\/cisplatin and methotrexate\/vinblastine\/doxorubicin\/cisplatin in patients with locally advanced and metastatic bladder cancer. Ann Oncol 17(Suppl 5):v118\u2013v122","journal-title":"Ann Oncol"},{"issue":"3","key":"3316_CR29","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.eururo.2014.03.003","volume":"66","author":"JJ Leow","year":"2014","unstructured":"Leow JJ, Martin-Doyle W, Fay AP, Choueiri TK, Chang SL, Bellmunt J (2014) A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol 66(3):529\u2013541","journal-title":"Eur Urol"},{"issue":"1","key":"3316_CR30","first-page":"31.e17-24","volume":"32","author":"FA Yafi","year":"2014","unstructured":"Yafi FA, Tanguay S, Rendon R et al (2014) Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome. Urol Oncol 32(1):31.e17-24","journal-title":"Urol Oncol"},{"issue":"3","key":"3316_CR31","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/cncr.22031","volume":"107","author":"A Dash","year":"2006","unstructured":"Dash A, Galsky MD, Vickers AJ et al (2006) Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 107(3):506\u2013513","journal-title":"Cancer"},{"issue":"4","key":"3316_CR32","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.eururo.2010.06.029","volume":"58","author":"MG Kaag","year":"2010","unstructured":"Kaag MG, O\u2019Malley RL, O\u2019Malley P et al (2010) Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol 58(4):581\u2013587","journal-title":"Eur Urol"},{"key":"3316_CR33","first-page":"1985","volume":"8","author":"IH Shao","year":"2014","unstructured":"Shao IH, Lin YH, Hou CP et al (2014) Risk factors associated with ineligibility of adjuvant cisplatin-based chemotherapy after nephroureterectomy. Drug Des Dev Ther 8:1985\u20131990","journal-title":"Drug Des Dev Ther"},{"issue":"11","key":"3316_CR34","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.3390\/toxins2112490","volume":"2","author":"RP Miller","year":"2010","unstructured":"Miller RP, Tadagavadi RK, Ramesh G, Reeves WB (2010) Mechanisms of cisplatin nephrotoxicity. Toxins (Basel) 2(11):2490\u20132518","journal-title":"Toxins (Basel)"},{"issue":"9","key":"3316_CR35","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/sj.ki.5002786","volume":"73","author":"N Pabla","year":"2008","unstructured":"Pabla N, Dong Z (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73(9):994\u20131007","journal-title":"Kidney Int"},{"issue":"1","key":"3316_CR36","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000362604","volume":"87","author":"S Kobayashi","year":"2014","unstructured":"Kobayashi S, Ueno M, Ohkawa S, Irie K, Goda Y, Morimoto M (2014) Renal toxicity associated with weekly cisplatin and gemcitabine combination therapy for treatment of advanced biliary tract cancer. Oncology 87(1):30\u201339","journal-title":"Oncology"},{"key":"3316_CR37","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1183\/09031936.00055110","volume":"37","author":"C M\u00e1th\u00e9","year":"2011","unstructured":"M\u00e1th\u00e9 C, Boh\u00e1cs A, Duffek L et al (2011) Cisplatin nephrotoxicity aggravated by cardiovascular disease and diabetes in lung cancer patients. Eur Respir J 37:888\u2013894","journal-title":"Eur Respir J"},{"key":"3316_CR38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.tox.2016.06.011","volume":"359\u2013360","author":"K Hosohata","year":"2016","unstructured":"Hosohata K, Washino S, Kubo T, Natsui S, Fujisaki A, Kurokawa S, Ando H, Fujimura A, Morita T (2016) Early prediction of cisplatin-induced nephrotoxicity by urinary vanin-1 in patients with urothelial carcinoma. Toxicology 359\u2013360:71\u201375","journal-title":"Toxicology"},{"issue":"9","key":"3316_CR39","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1002\/cncr.10990","volume":"97","author":"M Nogu\u00e9-Aliguer","year":"2003","unstructured":"Nogu\u00e9-Aliguer M, Carles J, Arrivi A et al (2003) Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy. Cancer 97(9):2180\u20132186","journal-title":"Cancer"},{"issue":"4","key":"3316_CR40","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00280-013-2098-9","volume":"71","author":"JH Park","year":"2013","unstructured":"Park JH, Lee SW, Kim HS et al (2013) Combination of gemcitabine and carboplatin as first line treatment in elderly patients or those unfit for cisplatin-based chemotherapy with advanced transitional cell carcinoma of the urinary tract. Cancer Chemother Pharmacol 71(4):1033\u20131039","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"3316_CR41","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2008.09.017","volume":"45","author":"NC Daw","year":"2009","unstructured":"Daw NC, Gregornik D, Rodman J et al (2009) Renal function after ifosfamide, carboplatin and etoposide (ICE) chemotherapy, nephrectomy and radiotherapy in children with Wilms tumour. Eur J Cancer 45(1):99\u2013106","journal-title":"Eur J Cancer"},{"issue":"2","key":"3316_CR42","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.2014.59.7302","volume":"34","author":"JH Beumer","year":"2016","unstructured":"Beumer JH, Ding F, Tawbi H et al (2016) Effect of renal dysfunction on toxicity in three decades of cancer therapy evaluation program-sponsored single-agent phase I studies. J Clin Oncol 34(2):110\u2013116","journal-title":"J Clin Oncol"},{"issue":"2","key":"3316_CR43","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00280-016-2966-1","volume":"77","author":"Y Funakoshi","year":"2016","unstructured":"Funakoshi Y, Fujiwara Y, Kiyota N et al (2016) Validity of new methods to evaluate renal function in cancer patients treated with cisplatin. Cancer Chemother Pharmacol 77(2):281\u2013288","journal-title":"Cancer Chemother Pharmacol"},{"issue":"19","key":"3316_CR44","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.2005.04.3091","volume":"24","author":"GV Raj","year":"2006","unstructured":"Raj GV, Iasonos A, Herr H, Donat SM (2006) Formulas calculating creatinine clearance are inadequate for determining eligibility for cisplatin-based chemotherapy in bladder cancer. J Clin Oncol 24(19):3095\u20133100","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3316-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3316-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3316-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T05:56:48Z","timestamp":1602136608000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3316-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,22]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["3316"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3316-7","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,22]]}}}